Research programme: CYP1-activated cancer therapy - Spear TherapeuticsAlternative Names: CYP1-activated cancer therapy research programme - SPEAR; DMU212; DMU214; DMU291
Latest Information Update: 28 Jul 2016
At a glance
- Originator Spear Therapeutics
- Developer Incanthera
- Class Stilbenes
- Mechanism of Action Apoptosis stimulants; Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 May 2005 Preclinical trials in Cancer in United Kingdom (unspecified route)